Document:

<PAGE>

                                                                EXHIBIT 10.20

                          STRATEGIC ALLIANCE AGREEMENT
                       Promedix.com, Inc. and Omnicell.com

         This Strategic Alliance Agreement ("Agreement") is entered into this
6th day of June, 2000 ("Effective Date") by and between Omnicell.com, a
California corporation ("Omnicell"), and Promedix.com, Inc. a Delaware
corporation ("Promedix") (collectively "Parties").

1.   PURPOSE.     Omnicell is in the business of maintaining a proprietary
     Internet-based electronic requisition and procurement system through its
     Omnibuyer(TM)and Omnisupplier(TM)applications ("Omnibuyer Services") to
     Omnicell customers ("Customers") for medical/surgical supplies, durable
     medical products, pharmaceutical supply and general supplies and services
     to hospitals, acute care treatment, long-term care and home-care treatment
     facilities. Promedix is in the business of maintaining a proprietary
     Internet-based electronic procurement system application ("Promedix
     System") for specialty medical products ("Products"). The Parties wish to
     enter into a strategic alliance to jointly market the Promedix System and
     services to current and potential Omnicell Customers and potential Promedix
     suppliers ("Suppliers") of Products.

2.   LICENSE AND USE OF THE PROMEDIX SYSTEM.

     2.1 LICENSE. Promedix grants Omnicell a non-exclusive, non-transferable,
         and worldwide license to use the Promedix System for internal purposes
         ("License"). No right is granted to use the Promedix System in
         combination with procurement software provided by other vendors.

     2.2 OMNICELL CUSTOMER USE. Promedix shall enter into a Promedix Customer
         Agreement with Omnicell Customers whereby Promedix shall assign a
         password ("Password") and a unique identifier ("User ID") to each
         Omnicell Customer to enable access and use of the Promedix System.

     2.3 OBLIGATIONS. Omnicell shall not (i) copy, alter, modify or adapt the
         Promedix System or data from the Promedix System, (ii) decompile,
         disassemble, or reverse engineer the Promedix System, (iii) rent,
         lease, distribute, transfer, reproduce or externally display the
         Promedix System, or (iv) time share, sublicense, operate as a service
         bureau using the Promedix System, or otherwise perform transactions for
         other parties using the Promedix System.

     2.4 SOURCE CODE LICENSE. This License does not grant access to or provide
         any rights in source code. The Software may be used only in binary
         executable form.

     2.5 OWNERSHIP. Promedix shall own all right, title and interest in and to
         the Promedix System and all modifications thereto. Title to, or
         ownership of the Promedix System (including any adaptations or copies)
         is not transferred to Omnicell under this Agreement.

     2.6 EXPORT RESTRICTIONS. Omnicell may not download, export or re-export the
         Software or any underlying information or technology of the Promedix
         System in violation of any export provisions of the United States or
         any other applicable jurisdiction, including without limitation, the
         Export Administration Act of 1979 and related regulations.

3.   STRATEGIC ALLIANCE COMMITMENTS.

     3.1  INTEGRATION. Promedix will become a supplier of specialty medical
          Products and services to Omnicell Customers through the integration of
          Promedix' electronic marketplace site. The Promedix electronic
          marketplace will be integrated with OmniSupplier or MarketSite.net
          "Supplier Hosted" configuration in accordance with an implementation
          and integration schedule to be agreed by the Parties within sixty (60)
          days of the Effective Date.

<PAGE>

     3.2 OMNICELL CUSTOMERS. Promedix may execute Customer agreements with
     Omnicell-introduced Customers that shall terminate or expire simultaneous
     to the termination or expiration of this Agreement.

     3.3 PROMEDIX SUPPLIERS. Promedix may execute Supplier agreements with
     Omnicell-introduced Suppliers. Such Supplier agreements may survive the
     termination or expiration terms of this Agreement.

4.   TRANSACTION FEES. Within thirty (30) days after the end of each month,
     Promedix shall pay Omnicell a percentage of the aggregate dollar value of a
     purchase order received by Promedix from Omnicell Customers for procurement
     services as follows:

         (a)  For Promedix Suppliers with Usage Fees greater than [*] percent
              ([*]%), the transaction fee payable by Promedix to Omnicell shall
              be [*] percent ([*]%) of the aggregate Purchase Order amount.

         (b)  For Promedix Suppliers with Usage Fees of [*] percent ([*]%) or
              less, the transaction fee payable by Promedix to Omnicell shall be
              [*] percent ([*]%) of the aggregate Omnicell Customer's Purchase
              Order amount.

     Usage Fees are the difference in the price paid to a Supplier by Promedix
     and the price charged to a Customer by Promedix, expressed as a function of
     the price paid by the Customer. Invoice values are less any shipping or
     taxes included on invoice.

5.   JOINT MARKETING. The Parties shall each designate a liaison ("Liaison") to
     serve as the their contact representative responsible for the development
     and deployment of all joint marketing operations. The Liaisons shall
     participate in a business operations review meeting every month by
     conference call and every quarter in person to be held alternatively at the
     Parties' respective sites. The Parties will support joint marketing and
     sales initiatives as agreed upon in advance by each Party's Liaison. These
     initiatives may include but shall not be limited to items such as:

              (a) Joint speaking engagements at industry conferences (within
                  certain parameters agreeable to each Party);

              (b) Joint sponsorship of educational marketing seminars (within
                  certain parameters agreeable to each Party);

              (c) Cooperative marketing and cooperative advertising in industry
                  publications and periodicals (within certain parameters
                  agreeable to each Party); or

              (d) Joint sales calls and proposal development with targeted
                  clients.

     5.1 MARKETING EXPENSES. Expenses associated with joint marketing and sales
         activities will be borne by each Party as agreed prior to incurring the
         expenses.

6.   REFERRALS. Either Party may choose to refer the other Party's products
     and/or services to its respective current and potential Omnicell Customers
     and potential Promedix Suppliers ("Clients"). All referrals shall be based
     upon the business needs identified by such Clients. In the case of such
     referrals, neither Party expects to receive a commission, finder's fee, or
     other similar financial incentive from the other Party. The Parties
     recognize and agree that they may refer the Products and/or services of
     other vendors or consultants to their current or prospective Clients. Each
     of the Parties shall be responsible for its own employees and for effecting
     the work and cost for which it has responsibility. In addition, each Party
     shall be exclusively responsible for any liability associated with its
     respective proposals or engagements. Other than as specifically provided
     herein, neither Party shall be obligated to collaborate with the other
     Party in any particular instance.

[*]  CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS UNDER 17.C.F.R. SECTION 200.80(b)(4), 200.83 AND
230.406.

<PAGE>

     6.1 OMNIBUYER ACCOUNT CUSTOMERS. Omnicell agrees to promote Promedix and
         the Promedix services to all of its OmniBuyer Customers, including but
         not limited to hospital clinics, acute care centers. Omnicell will
         introduce Promedix to each future Omnicell Customer account signed by
         Omnicell for OmniBuyer Services within thirty (30) days of that account
         being signed by Omnicell. Omnicell will introduce Promedix to its
         existing Customers within sixty (60) days of the Effective Date.

     6.2 SUPPLIER RECRUITMENT. Omnicell agrees to collaborate with Promedix in
         approaching potential Promedix Suppliers. Omnicell will introduce
         Promedix to all of Omnicell's current signed specialty medical
         Suppliers who are not already signed with Promedix within sixty (60)
         days of the Effective Date. Omnicell and Promedix agree to meet
         quarterly to discuss Supplier adoption and share Supplier lists.

7.   MARKETING AND REFERRAL COSTS. Neither Party shall be liable to the other
     for any cost, expense or liability arising out of this Agreement nor its
     implementation except as otherwise specified in this Agreement.
     Furthermore, the Parties agree that any and all costs, expenses, or
     liabilities of the Parties arising out of this Agreement or its
     implementation shall be the responsibility of each Party separately and
     individually unless agreed to by the Parties in writing.

8.   AUDIT. During the term of this Agreement and for one (1) year after the
     termination or expiration hereof, Omnicell shall have the right, at its
     expense to audit Promedix Supplier Usage Fees and Promedix shall have the
     right, at its expense to audit Omnicell's use of Omnicell's Customer
     identification information. Such audit shall not interfere unreasonably
     with either Party's business activities, breach confidentiality terms, and
     shall be conducted upon no less than ten (10) business days prior written
     notice to the other Party.

9.   CUSTOMER ORDERS AND PAYMENT TERMS. Customer's purchases of Products through
     the Promedix System shall be subject to the terms and conditions set forth
     in the Promedix Customer Enterprise Agreement. The Customer will submit
     orders for Products through the Promedix System. Promedix shall invoice
     Customer and receive payment from Customer. Until full payment has been
     received, Promedix reserves a purchase money security interest in the
     Products sold.

10.  INTELLECTUAL PROPERTY RIGHTS. Except as specifically contained herein,
     nothing contained in this Agreement shall be construed as granting to the
     other Party either expressly, by implication, estoppel, or otherwise, any
     license under any invention or patent, trademark, copyright, or trade
     secret, owned or controlled by the disclosing Party.

11.  TERM AND TERMINATION This Agreement shall become effective as of the
     Effective Date and shall remain in effect for a period of three (3) years
     after the first day of the month following the Effective Date, and shall
     automatically renew for an additional one (1) year period unless terminated
     earlier in accordance with the provisions of this Section.

     11.1.TERMINATION FOR CONVENIENCE. Either Party may terminate this Agreement
          solely for convenience by giving the other party at least ninety (90)
          days prior written notice.

     11.2.TERMINATION FOR CAUSE. Either Party may terminate this Agreement for
          the substantial breach by the other Party of any material term. The
          terminating Party shall first give the breaching Party written notice
          of the alleged breach and a reasonable period of at least thirty (30)
          days in which to cure the alleged breach. If the breach is not cured
          within the cure period, the terminating party may terminate this
          Agreement upon written notice to the breaching Party.

     11.3.EFFECT OF TERMINATION. Upon the termination of this Agreement,
          Omnicell shall immediately cease all use of the Promedix System and
          each Party shall return to the other Party all software along with all
          Confidential Information belonging to such other Party.

12.  PUBLIC RELEASE OF INFORMATION. The Parties shall jointly and individually
     issue press releases with prior written approval by the Parties to
     communicate the subject matter related to this Agreement.

<PAGE>

13.  NON-SOLICITATION. The Parties agree to not knowingly engage in any attempt
     to solicit for employment, or to engage as independent contractors, whether
     directly or indirectly, such of the other's employees or independent
     contractors who have worked on operations in connection with this Agreement
     or who have provided training, support or other development, technical,
     sales or marketing assistance which is the subject of or provided for under
     this Agreement for the period ending one year after the termination of this
     Agreement, except as may be otherwise agreed to in writing by both Parties.

14.  EXCLUSIVITY The Parties agree that during the term of this Agreement each
     Party will be free to enter into relationships with other firms conditioned
     by the strategic alliance commitments of this Agreement. Each Party is also
     free to prepare and submit proposals independent of the other Party
     conditioned by the strategic alliance commitments of this Agreement. Any
     effort made by either Party pursuant to this subparagraph is subject to the
     confidentiality provisions herein.

15.  CONFIDENTIAL INFORMATION. The Parties anticipate it may be necessary
     for either or both Parties to furnish to the other information of a
     confidential and proprietary nature, including information furnished to
     Omnicell or Promedix by clients of either Party. Such information may be
     oral, written, or in machine-readable form which may comprise data,
     knowledge, ideas or other information of an important and competitive
     nature. Each of the Parties agrees that it will use the same degree of care
     to protect such information from disclosure to third parties as is used to
     protect its own information of similar importance. Disclosures of such
     information shall be restricted to those individuals who are bound to this
     Agreement or similar confidentiality provisions. The information furnished
     to either Party may only be used and reproduced in performance of its
     respective obligations under this Agreement. Upon expiration or termination
     of this Agreement, each Party shall return all tangible Confidential
     Information received from the other Party. These confidentiality
     obligations shall survive for three (3) years after expiration or
     termination of this Agreement. The restrictions of reproduction,
     disclosure, or use of confidential information shall not apply if any of
     the following conditions exist:

     15.1.If the information has been developed independently by the
          receiving Party;

     15.2.If the information has been lawfully received from other sources;

     15.3.If the information is published by the disclosing Party or is
          disclosed to others, without restriction;

     15.4.If such information otherwise comes within the public  knowledge
          or becomes generally known to the public;

     15.5.If such information is disclosed pursuant to a validly issued court
          order, subpoena or other legal process provided that promptly upon
          receiving such order, subpoena or process, the Party would notify the
          other Party to aid in affording an opportunity to seek a protective
          order covering the subpoenaed material; or

     15.6.If such information is known to receiving Party prior to disclosure
          hereunder.

16.  LIMITED WARRANTY

     16.1.PRODUCTS. Promedix provides no warranty with respect to the Products
          sold hereunder. The only warranties on the Products will be those
          provided directly from the Supplier. Except to the extent expressly
          stated in Supplier's warranty, THE PRODUCTS ARE SOLD "AS IS" AND
          PROMEDIX DISCLAIMS AND EXCLUDES BY MUTUAL AGREEMENT ALL WARRANTIES,
          CONDITIONS, REPRESENTATIONS, STATEMENTS AND LIABILITY WHETHER OR NOT
          EXPRESSLY SET OUT IN ANY OTHER DOCUMENT OR IMPLIED BY LAW, STATUTE, OR
          CUSTOM OR WHICH WOULD OTHERWISE BE APPLICABLE THERETO, INCLUDING BUT
          NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
          PARTICULAR PURPOSE, TITLE OR NON-INFRINGEMENT.

<PAGE>

     16.2.SERVICES AND PROMEDIX SYSTEM. OMNICELL.COM PROVIDES SERVICES, AND
          PROMEDIX PROVIDES SERVICES AND THE PROMEDIX SYSTEM "AS IS" AND EACH
          PARTY DISCLAIMS AND EXCLUDES ANY AND ALL OTHER EXPRESS, IMPLIED, AND
          STATUTORY WARRANTIES, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF
          GOOD TITLE, WARRANTIES AGAINST INFRINGEMENT, AND THE IMPLIED
          WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.
          NEITHER PARTY WARRANTS THAT THEIR RESPECTIVE SERVICES/SYSTEM WILL
          SATISFY THE OTHER PARTY'S, THE SUPPLIER'S OR CUSTOMER'S REQUIREMENTS
          OR THAT SUCH SERVICES/SYSTEM IS WITHOUT DEFECT OR ERROR OR THAT THE
          OPERATION OF THE SAME WILL BE UNINTERRUPTED. NEITHER PARTY MAKES ANY
          WARRANTIES REGARDING ANY TECHNICAL SERVICES OR SUPPORT.

17.  OMNICELL  INDEMNIFICATION.  Omnicell shall indemnify, defend, and
     hold harmless Promedix, Customers, Suppliers, and their respective
     employees, agents, successors, officers, and assigns, from any suits,
     losses, claims, demands, liabilities, costs and expenses (including
     attorney and accounting fees) that Promedix, Customers or Supplier may
     sustain or incur arising from (a) Omnicell's failure to comply with any
     applicable laws and regulations (including without limitation those
     regarding the export of products or technology abroad, the Toxic Substance
     Control Act, and the Food, Drug and Cosmetic Act) or to obtain any licenses
     or approvals from the appropriate government agencies necessary to
     concerning the purchase, sell and use the Products, or (b) Omnicell's
     breach of any of its obligations set forth in this Agreement. In connection
     with the foregoing indemnity obligation, Promedix will provide Omnicell
     with (i) prompt written notice of such claim; (ii) control over the defense
     and settlement of such claim; and (iii) proper and full information and
     assistance at Promedix's expense to settle and/or defend any such claim.
     Notwithstanding the foregoing, Omnicell shall not settle any such claim,
     suit or proceeding without the written consent of Promedix, which shall not
     be unreasonably withheld.

     17.1.OMNICELL THIRD PARTY INFRINGEMENT INDEMNIFICATION. Omnicell agrees, at
          its own expense, to defend or at its option to settle any claim or
          action brought against Promedix on the issue of infringement of any
          patent of any Omnicell System, including Commerce One, and to
          indemnify and hold Promedix harmless against any and all suits,
          losses, claims, demands, liabilities, expenses, damages and costs,
          including legal fees, that are attributable to such claim. Omnicell
          shall be relieved of the foregoing obligation unless Promedix provides
          Omnicell with (a) prompt written notice of such claim or action, (b)
          sole control and authority over the defense or settlement of such
          claim or action and (c) proper and full information and reasonable
          assistance, at Omnicell's expense to defend and/or settle any such
          claim or action.

         17.1.1. ENJOINED USE. If any Omnicell System, including Commerce One,
               is held to infringe and use is enjoined, Promedix agrees to
               permit Omnicell, at Omnicell's option and expense, to: (a)
               replace or modify the Omnicell System so that it becomes
               non-infringing; or (b) procure for Promedix the right to continue
               to use the Omnicell System, or, if the foregoing alternatives are
               not reasonably available to Omnicell, (c) terminate this
               Agreement.

         17.1.2. INDEMNIFICATION LIMITATION. OMNICELL'S LIABILITY UNDER THIS
               SECTION 17.1. "OMNICELL THIRD PARTY INFRINGEMENT
               INDEMNIFICATION," IS LIMITED BY SECTION "LIMITATION OF
               LIABILITY." THIS SECTION 17.1.2. STATES THE ENTIRE LIABILITY AND
               OBLIGATION OF OMNICELL TO PROMEDIX AND THE EXCLUSIVE REMEDY OF
               PROMEDIX , REGARDING ANY ALLEGED OR ACTUAL INFRINGEMENT OR
               MISAPPROPRIATION OF ANY INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD
               PARTY.

18.  PROMEDIX  INDEMNIFICATION.   Promedix shall indemnify, defend, and hold
     harmless Omnicell, Customers, Suppliers, and their respective employees,
     agents, successors, officers, and assigns, from any suits, losses, claims,
     demands, liabilities, costs and expenses (including attorney and accounting
     fees) that Omnicell, Customers or Supplier may sustain or incur arising
     from (a) Promedix's failure to comply with any applicable laws and
     regulations (including without limitation those regarding the export of
     products or technology abroad, the Toxic Substance Control Act, and the
     Food, Drug and Cosmetic Act) or to obtain any licenses or approvals from
     the appropriate government agencies

<PAGE>

     necessary to concerning the purchase, sell and use the Products, or (b)
     Promedix's breach of any of its obligations set forth in this Agreement.
     In connection with the foregoing indemnity obligation, Omnicell will
     provide Promedix with (i) prompt written notice of such claim; (ii)
     control over the defense and settlement of such claim; and (iii) proper
     and full information and assistance at Omnicell's expense to settle
     and/or defend any such claim. Notwithstanding the foregoing, Promedix
     shall not settle any such claim, suit or proceeding without the written
     consent of Omnicell, which shall not be unreasonably withheld.

     18.1.PROMEDIX THIRD PARTY INFRINGEMENT INDEMNIFICATION. Promedix agrees, at
          its own expense, to defend or at its option to settle any claim or
          action brought against Omnicell on the issue of infringement of any
          patent of the Promedix System, and to indemnify and hold Customer
          harmless against any and all suits, losses, claims, demands,
          liabilities, expenses, damages and costs, including legal fees, that
          are attributable to such claim. Promedix shall be relieved of the
          foregoing obligation unless Omnicell provides Promedix with (a) prompt
          written notice of such claim or action, (b) sole control and authority
          over the defense or settlement of such claim or action and (c) proper
          and full information and reasonable assistance, at Promedix 's expense
          to defend and/or settle any such claim or action.

         18.1.1. ENJOINED USE. If the Promedix System is held to infringe and
               use of the Promedix System is enjoined, Omnicell agrees to permit
               Promedix, at Promedix's option and expense, to: (a) replace or
               modify the Promedix System so that it becomes non-infringing; or
               (b) procure for Customer the right to continue to use the
               Promedix System, or, if the foregoing alternatives are not
               reasonably available to Promedix, (c) terminate this Agreement.

         18.1.2. INDEMNIFICATION LIMITATION. PROMEDIX'S LIABILITY UNDER THIS
               SECTION "PROMEDIX THIRD PARTY INFRINGEMENT INDEMNIFICATION," IS
               LIMITED BY SECTION "LIMITATION OF LIABILITY." THIS SECTION
               18.1.2. STATES THE ENTIRE LIABILITY AND OBLIGATION OF PROMEDIX TO
               OMNICELL AND THE EXCLUSIVE REMEDY OF OMNICELL, REGARDING ANY
               ALLEGED OR ACTUAL INFRINGEMENT OR MISAPPROPRIATION OF ANY
               INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.

19.  LIMITATION OF LIABILITY. THE PARTIES SHALL NOT BE LIABLE TO EACH OTHER OR
     ANY OTHER PARTY UNDER THIS AGREEMENT FOR COSTS OF PROCUREMENT OF SUBSTITUTE
     PRODUCTS OR SERVICES, ANY LOSS OF BUSINESS, LOSS OF USE OR DATA,
     INTERRUPTION OF BUSINESS, LOST PROFITS OR GOODWILL, OR FOR INDIRECT,
     SPECIAL, RELIANCE, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL LOSS OR DAMAGE OF
     ANY KIND ARISING OUT OF THIS AGREEMENT, WHETHER IN A CONTRACT, TORT, OR
     OTHER ACTION FOR OR ARISING OUT OF BREACH OF WARRANTY, BREACH OF CONTRACT,
     DELAY, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, EVEN IF PROMEDIX OR
     OMNICELL HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS, AND
     NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

20.  MISCELLANEOUS

     20.1.LAWS. This Agreement shall be governed by and interpreted in
          accordance with the laws of the State of Utah and applicable federal
          (U.S.) laws. The choice of law rules forming part of the selected
          national law are excluded. Each party will, at its own expense, comply
          with any applicable law, statute, ordinance, administrative order,
          rule and regulation.

     20.2.DISPUTE RESOLUTION. The parties agree to negotiate in good faith to
          resolve all disputes arising under this Agreement. This meeting must
          be held before either party may seek any other method of dispute
          resolution, including judicial or governmental resolutions.
          Notwithstanding the foregoing, this section shall not be construed to
          prevent either Party from seeking and obtaining temporary equitable
          remedies, including injunctive relief.

     20.3.SEVERABILITY; MODIFICATION; WAIVER;. If any of the provisions of this
          Agreement are held to be invalid under any applicable statute or rule
          of law, then they are deemed omitted to that extent.

<PAGE>

          Except for Promedix's right to revise Product information and
          prices, no alteration, amendment, waiver, cancellation or any other
          change in any term or condition of this Agreement shall be valid or
          binding on any party unless both parties mutually assent to in
          writing. The waiver of one breach or default or any delay in
          exercising any rights shall not constitute a waiver of any
          subsequent breach or default.

     20.4.ENTIRE AGREEMENT. This Agreement sets forth the entire agreement and
          understanding between the parties as to its subject matter and is
          intended to be the final, complete, and exclusive statement of the
          terms of such agreement and understanding. This Agreement supersedes
          all other prior and contemporaneous agreements and statements on these
          subjects. Each party warrants that in entering into this Agreement, it
          has not relied upon or been induced by any representation or statement
          not expressly set forth in this Agreement.

     20.5.NO EMPLOYMENT OR AGENCY. Promedix and Omnicell are independent
          contractors. Nothing contained in this Agreement shall be construed to
          constitute Promedix and Omnicell as partners, agents or joint
          venturers with respect to this Agreement. Neither Omnicell nor
          Promedix has the authority to bind the other or to incur any liability
          for, or otherwise act on behalf of, the other.

     20.6.ASSIGNMENT. This Agreement shall be binding upon the parties and their
          respective successors and assigns. No party may assign any of its
          rights, obligations or privileges (by operation of law or otherwise)
          hereunder without the prior written consent of the other party, which
          shall not be unreasonably withheld, provided, that Promedix shall have
          the right to assign its rights, obligations and privileges hereunder
          to a successor in business or an acquirer of all or substantially all
          of its business or assets to which this Agreement pertains without
          obtaining the consent of Omnicell.

     20.7.NOTICES. Any notice required or permitted to be given by either party
          under this Agreement shall be in writing and shall be personally
          delivered or sent by certified or registered letter, or by telecopy,
          by a courier service, or by electronic mail to the other party at its
          address first set forth above, or such new address as may from time to
          time be supplied by the parties. If mailed, notices will be deemed
          effective three (3) working days after deposit, postage prepaid, in
          the mail. If sent by telecopy, courier, or electronic mail, notices
          will be deemed effective upon confirmation of receipt by addressee.

     20.8.SURVIVABILITY. Sections 8, 10, 13, 15, 16, 17, 18, 19 and 20 and all
          payment obligations incurred prior to the termination of this
          Agreement, shall survive such termination.

     20.9.Force Majeure. Neither Party shall be responsible for failure to
          fulfill its obligations under this Agreement due to causes beyond its
          reasonable control.

Promedix and Omnicell each represent that they have read and understand this
Agreement, that by signing below they agree to be bound by the terms and
conditions hereof, and that they have caused this Agreement to be executed by
its duly authorized representative.

OMNICELL.COM                             PROMEDIX .COM, INC.

BY: /s/ Jeffrey L. Arbuckle              BY: /s/ Barrie Keiser
   ------------------------------           -----------------------------------
PRINT NAME: Jeffrey L. Arbuckle          PRINT NAME: Barrie Keiser
           ----------------------                   ---------------------------
TITLE: V.P. e-Commerce                   TITLE: President
      ---------------------------              --------------------------------<PAGE>

                                                              EXHIBIT 10.1

                       THIRD AMENDMENT TO CREDIT AGREEMENT

     THIS THIRD AMENDMENT TO CREDIT AGREEMENT (the "Third Amendment") is made
and dated as of the 5th day of November, 1999, by and among QAD INC., a
Delaware corporation (the "Borrower"), BANK ONE, NA ("Bank One"), formerly
known as THE FIRST NATIONAL BANK OF CHICAGO, in its capacity as the sole
current Lender, and BANK ONE, as agent for the Lenders (in such capacity, the
"Agent").

                                    RECITALS

     A. Pursuant to that certain Credit Agreement dated as of April 19, 1999 by
and among the Borrower, the Lender and the Agent (as amended from time to time,
the "Credit Agreement"), the Lender agreed to extend credit to the Borrower on
the terms and subject to the conditions set forth therein. All capitalized terms
not otherwise defined herein shall have the meanings given to such terms in the
Credit Agreement.

     B. The Borrower, the Agent and the Lender have agreed to amend the Credit
Agreement in certain respects as set forth more particularly herein.

     NOW, THEREFORE, in consideration of the foregoing Recitals and for other
valuable consideration, the receipt and adequacy of which are hereby
acknowledged, the parties hereto hereby agree as follows:

                                    AGREEMENT

     1. FINANCING OF CERTAIN REAL PROPERTY. To reflect the agreement of the
Agent and the Lender to permit the Borrower to obtain financing secured by
certain existing Property owned by the Borrower, effective as of the Effective
Date (as defined in Paragraph 3 below):

         (a) Section 6.11 of the Credit Agreement is hereby amended to delete
the existing subsection (iv) and to add new subsections (iv) and (v) to read in
their entirety as follows:

              "(iv) Indebtedness in an amount not to exceed $7,500,000 secured
by Liens on the Ortega Property and the Mark Hill/Twin Pines Property as
provided in Section 6.15(viii) below.

              (v) Other Indebtedness in an amount not to exceed $3,000,000 in
the aggregate outstanding at any date."

         (b) Section 6.15 of the Credit Agreement is hereby amended to add a new
subsection (viii) thereto to read in its entirety as follows:

              "(viii) Liens on the Ortega Property and the Mark Hill/Twin Pines
Property securing Indebtedness in a principal amount not to exceed $7,500,000;
provided that such Liens shall not extend to any property other than the Ortega
Property and the Mark Hill/Twin Pines Property, respectively."

         (c) Section 2.1(ii) is hereby amended to read in its entirety as
follows:

<PAGE>

              "(ii) the aggregate Dollar Amount of Loans and Facility LCs
outstanding hereunder shall not exceed the lesser of:

                    (1) the Aggregate Commitment (as reduced concurrently
therewith) minus the sum of: (i) the aggregate Dollar Amount of Loans and
Facility LCs outstanding hereunder, plus (ii) the aggregate Dollar Amount of
Related Facility Loans outstanding under the Related Facility Credit Agreements,
and

                    (2) the Collateral Value of the Borrowing Base minus the sum
of: (i) the aggregate Dollar Amount of Loans and Facility LCs outstanding under
the Credit Agreement, plus (ii) the aggregate Dollar Amount of Parent Collateral
Supported Related Facility Loans outstanding under the Related Facility Credit
Agreements; and"

         (d) Section 6.13 of the Credit Agreement is hereby amended to amend
subsection (ii) and renumber it as subsection (iii) and to add a new subsection
(ii), such amended and renumbered subsection (iii) and new subsection (ii) to
read in their entirety as follows:

              "(ii) Transfers of the Ortega Property and/or the Mark Hill/Twin
Pines Property to single purpose Subsidiaries in connection with the financings
permitted under Sections 6.11(iv) and 6.15(viii)."

              (iii) Other leases, sales and dispositions of its Property that,
together with all other Property of the Borrower and its Subsidiaries previously
leased, sold or disposed of (other than inventory in the ordinary course of
business) as permitted by this Section during the twelve-month period ending
with the month in which any such lease, sale or other disposition occurs, with a
fair market value not to exceed $5,000,000."

         (e) Article I of the Credit Agreement is hereby amended to insert the
following new definitions, in correct alphabetical order, to read in their
entirety as follows:

              "'Ortega Property' means that certain Property commonly referred
to as 2111 Ortega Hill road, Summerland, Santa Barbara County, California."

              "'Mark Hill/Twin Pines Property' means that certain Property
commonly referred to as 6390 Via Real, Carpinteria, Santa Barbara County,
California."

     2. REDUCTION IN COMMITMENT. In consideration of the agreement of the Agent
and the Lender to permit the incurrence of the secured Indebtedness referred to
in Paragraph 1 above, the Borrower, the Agent and the Lender hereby agree that
effective as of the Effective Date, the Commitment of Bank One, as the sole
current Lender under the Credit Agreement, shall be reduced from $30,000,000 to
$25,000,000, with the Aggregate Commitment thereby being reduced to $25,000,000.

     3. EFFECTIVE DATE. This Third Amendment shall be effective, retroactive to
the date first above written, upon the date upon which the Agent has received:

<PAGE>

              (a) A copy of this Third Amendment, duly executed by all parties
hereto, including the current Subsidiary Borrowers;

              (b) For payment to the Lender, immediately available funds in the
amount, if any, by which the aggregate Dollar Amount of Loans and Facility LCs
outstanding under the Credit Agreement after giving effect to the reduction in
Commitment set forth in Paragraph 2 above exceeds the lesser of:

                    (1) the Aggregate Commitment (as reduced concurrently
therewith) minus the sum of: (i) the aggregate Dollar Amount of Loans and
Facility LCs outstanding hereunder, plus (ii) the aggregate Dollar Amount of
Related Facility Loans outstanding under the Related Facility Credit Agreements,
and

                    (2) the Collateral Value of the Borrowing Base minus the sum
of: (i) the aggregate Dollar Amount of Loans and Facility LCs outstanding under
the Credit Agreement, plus (ii) the aggregate Dollar Amount of Parent Collateral
Supported Related Facility Loans outstanding under the Related Facility Credit
Agreements; and

         (c) Such corporate resolutions, incumbency certificates and other
authorizing documentation as the Agent may require.

     4. REAFFIRMATIONS. The Borrower hereby affirms and agrees that (a) the
execution and delivery by the Borrower of and the performance of its obligations
under this Third Amendment shall not in any way amend, impair, invalidate or
otherwise affect any of the obligations of the Borrower or the rights of the
Agent and the Lenders under the Borrower Security Agreement or any other
document, agreement or instrument made or given by the Borrower or any
Subsidiary Borrower in connection therewith, (b) the term "Secured Obligations"
as used in the Borrower Security Agreement and any Subsidiary Borrower Security
Agreement includes, without limitation, the Obligations of the Company under the
Credit Agreement as amended to date, including, without limitation, pursuant to
this Third Amendment, and (c) each of the Borrower Security Agreement and any
Subsidiary Borrower Security Agreement remains in full force and effect and
continues to constitute a first priority security interest in and lien upon the
Collateral.

     5. NO OTHER AMENDMENT. Except as expressly amended herein, the Credit
Agreement and other Loan Documents shall remain in full force and effect as
currently written.

     6. COUNTERPARTS. This Third Amendment may be executed in any number of
counterparts, each of which when so executed shall be deemed to be an original
and all of which when taken together shall constitute one and the same
agreement.

     7. REPRESENTATIONS AND WARRANTIES. The Borrower hereby represents and
warrants to the Agent and each Lender as follows:

         (a) The Borrower has the corporate power and authority and the legal
right to execute, deliver and perform this Third Amendment and has taken all
necessary corporate action to authorize the execution, delivery and performance
of this Third Amendment. This Third Amendment has been duly executed and
delivered on behalf of the Borrower and constitutes the legal, valid and binding
obligation of the Borrower, enforceable against the Borrower in accordance with
its terms.

<PAGE>

         (b) At and as of the date of execution hereof and at and as of
effective date hereof: (1) the representations and warranties of the Borrower
contained in the Credit Agreement and the other Loan Documents are accurate and
complete in all respects, and (2) there has not occurred a Default or an
Unmatured Default under the Credit Agreement.

     IN WITNESS WHEREOF, the parties hereto have caused this Third Amendment to
be executed as of the day and year first above written.

                        QAD INC., a Delaware corporation

                           By___________________________________________
                           Name_________________________________________
                           Title________________________________________

                           BANK ONE, NA, formerly known as THE FIRST NATIONAL
                           BANK OF CHICAGO, as the sole current Lender and as
                           the Agent

                           By __________________________________________
                           Name ________________________________________
                           Title _______________________________________

ACKNOWLEDGED AND AGREED TO
as of the day and year first above written:

QAD AUSTRALIA PTY LIMITED

By: __________________________
Name: ________________________
Title: _______________________

QAD EUROPE BV

By: __________________________
Name: ________________________
Title: _______________________

<PAGE>

QAD EUROPE LTD.

By: __________________________
Name: ________________________
Title: _______________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]